Adagene Inc. has announced a clinical collaboration with Incyte to initiate a Phase 1 study in 2026, evaluating the combination of muzastotug (ADG126) and INCA33890 in patients with microsatellite stable colorectal cancer (MSS CRC), both with and without liver metastases. This collaboration aims to explore the potential of muzastotug, a masked anti-CTLA-4 SAFEbody®, as a backbone for next-generation immuno-oncology therapies, particularly in a patient population that has shown resistance to current treatments.

This development is significant for the longevity and healthspan field as it highlights the ongoing shift towards innovative combination therapies in oncology. The combination of muzastotug with INCA33890, a bispecific antibody targeting TGFβR2 and PD-1, could enhance anti-tumor immune responses, especially in MSS CRC patients who typically have limited treatment options and a poor prognosis. The promising results from previous trials of muzastotug in combination with Merck’s KEYTRUDA® further validate its potential role in improving overall response rates and extending survival.

For professionals in the aging biology and therapeutic sectors, this collaboration underscores the importance of exploring novel immunotherapeutic strategies that address the unique challenges posed by cancers resistant to conventional treatments. As the study progresses, insights gained could significantly inform future therapeutic approaches and enhance the understanding of immune evasion mechanisms in colorectal cancer, ultimately contributing to improved patient outcomes in this challenging disease area.

Source: globenewswire.com